2. Signaling Pathways
  3. Anti-infection
  4. Arenavirus
  5. Arenavirus Inhibitor

Arenavirus Inhibitor

Arenavirus Inhibitors (17):

Cat. No. Product Name Effect Purity
  • HY-14805
    Tecovirimat
    		Inhibitor 99.88%
    Tecovirimat (ST-246) is an orally bioavailable and selective compound against orthopoxviruses including vaccinia, monkeypox, camelpox, cowpox, ectromelia (mousepox), smallpox and variola viruses. Tecovirimat is evaluated against vaccinia, cowpox virus, ectromelia virus with EC50 values of 0.01 μM, 0.48 μM and 0.05 μM, respectively. Tecovirimat targets the orthopoxvirus protein VP37 which is necessary for membrane envelopment of intracellular mature virus particles to form enveloped virus. Tecovirimat exerts antiviral activity on the target of the cowpox virus V061 gene, which is homologous to vaccinia virus F13L, encoding a major envelope protein (p37) required for production of extracellular virus.
  • HY-13560
    AVN-944
    		Inhibitor 99.89%
    AVN-944 (VX-944) is an orally active, potent, selective, noncompetitive and specific inhibitor of IMPDH (inosine monophosphate dehydrogenase). AVN-944 is an essential rate-limiting enzyme in de novo guanine nucleotide synthesis. AVN-944 is also an inhibitor of arenavirus RNA synthesis, and blocks arenavirus infection. AVN-944 has broad anti-cancer activities, and can be used for multiple myeloma (MM) and acute myeloid leukemia (AML) research.
  • HY-13963
    ZCL278
    		Inhibitor 98.49%
    ZCL278 is a selective Cdc42 inhibitor with Kds of 6.4 μM in fluorescence titration and 11.4 μM in surface plasmon resonance (SPR) measurement. ZCL278 is able to disrupt the Cdc42-ITSN interaction as well as GTP/GDP binding. ZCL278 has inhibitory effects on various enveloped viruses, but is ineffective against non-enveloped viruses. ZCL278 can be used for the studies of arsenic neurotoxicity and HER2-positive gastric cancer (GC).
  • HY-112762
    LHF-535
    		Inhibitor 99.14%
    LHF-535 is an antiviral agent extracted from patent WO2013123215A2, Compound 38, has EC50s of <1 μM, <1 μM, <1 μM, and 1-10 μM for Lassa, Machupo, Junin, and VSVg virus, respectively.
  • HY-101441
    ST-193
    		Inhibitor 99.93%
    ST-193 is a potent broad-spectrum arenavirus inhibitor; inhibits Guanarito, Junin, Lassa and Machupo virus with IC50 values of 0.44, 0.62, 1.4 and 3.1 nM, respectively.
  • HY-P0323A
    GP(33-41) TFA
    		Inhibitor 99.62%
    GP(33-41) TFA, a 9-aa-long peptide, is the optimal sequence of the GP1 epitope of lymphocytic choriomeningitis virus. GP(33-41) TFA can upregulate H-2Db molecules at the RMA-S (Db Kb) cell surface with a SC50 of 344 nM.
  • HY-114698
    Retro-2 cycl
    		Inhibitor 99.17%
    Retro-2 cycl (RN 1-001) is a retrograde transport inhibitor with antiviral activity. Retro-2 cycl (RN 1-001) inhibits JCPyV and HPV16 pseudoviruses, with an IC50 of 54 μM and 160 μM respectively.
  • HY-N10113
    Verrucarin J
    		Inhibitor ≥99.0%
    Verrucarin J (Muconomycin B) is a metabolite of the Myrothecium fungus family. Verrucarin J generates reactive oxygen species (ROS) and induces apoptosis of cancer cell lines, such as A549, HCT 116 and SW-620 cells. Verrucarin J shows activities against Candida albicans and Mucor miehei. Verrucarin J inhibits arenavirus Junin (JUNV) yield with an IC50 of 1.2 ng/mL.
  • HY-14805S
    Tecovirimat-d4
    		Inhibitor 99.14%
    Tecovirimat-d4 (ST-246-d4) is a deuterium-labelled Tecovirimat (HY-14805). Tecovirimat is an orally bioavailable and selective compound against orthopoxviruses [including vaccinia, monkeypox, camelpox, cowpox, ectromelia (mousepox), smallpox and variola viruses]. Tecovirimat is evaluated against vaccinia, cowpox virus, ectromelia virus with EC50 values of 0.01 μM, 0.48 μM and 0.05 μM, respectively. Tecovirimat targets the orthopoxvirus protein VP37 which is necessary for membrane envelopment of intracellular mature virus particles to form enveloped virus. Tecovirimat exerts antiviral activity on the target of the cowpox virus V061 gene, which is homologous to vaccinia virus F13L, encoding a major envelope protein (p37) required for production of extracellular virus. Tecovirimat could be used in the study for orthopoxvirus-induced diseases.
  • HY-101441A
    ST-193 hydrochloride
    		Inhibitor 98.76%
    ST-193 hydrochloride is a potent broad-spectrum arenavirus inhibitor; inhibits Guanarito, Junin, Lassa and Machupo virus with IC50 values of 0.44, 0.62, 1.4 and 3.1 nM, respectively.
  • HY-112762A
    (E)-LHF-535
    		Inhibitor 99.21%
    (E)-LHF-535 is the E-isomer of LHF-535. LHF-535 is an antiviral agent extracted from patent WO2013123215A2, Compound 38, has EC50s of <1 μM, <1 μM, <1 μM, and 1-10 μM for Lassa, Machupo, Junin, and VSVg virus, respectively.
  • HY-124871
    LASV inhibitor 3.3
    		Inhibitor 99.87%
    LASV inhibitor 3.3 is a Lassa fever virus (LASV) inhibitor. LASV inhibitor 3.3 binds with LASV glycoprotein (GP) and promotes virus membrane fusion and infection. LASV inhibitor 3.3 can be used for LASV infection research.
  • HY-P990166
    Anti-Mouse PSGL-1/CD162 Antibody (4RA10)
    		Inhibitor
    Anti-Mouse PSGL-1/CD162 Antibody (4RA10) is a rat-derived IgG1 κ type antibody inhibitor, targeting to mouse PSGL-1/CD162. Anti-Mouse PSGL-1/CD162 Antibody (4RA10) blocks PSGL signaling and inhibits leukocyte rolling. Anti-Mouse PSGL-1/CD162 Antibody (4RA10) can be used for the researches of inflammation, immunology and infection, such as pneumonia and lymphocytic choriomeningitis virus infection.
  • HY-14805A
    Tecovirimat monohydrate
    		Inhibitor 99.97%
    Tecovirimat (ST-246) monohydrate is the monohydrate form of Tecovirimat (HY-14805). Tecovirimat monohydrate is an orally bioavailable and selective compound against orthopoxviruses [including vaccinia, monkeypox, camelpox, cowpox, ectromelia (mousepox), smallpox and variola viruses]. Tecovirimat monohydrate is evaluated against vaccinia, cowpox virus, ectromelia virus with EC50 values of 0.01 μM, 0.48 μM and 0.05 μM, respectively. Tecovirimat monohydrate targets the orthopoxvirus protein VP37 which is necessary for membrane envelopment of intracellular mature virus particles to form enveloped virus. Tecovirimat monohydrate exerts antiviral activity on the target of the cowpox virus V061 gene, which is homologous to vaccinia virus F13L, encoding a major envelope protein (p37) required for production of extracellular virus. Tecovirimat monohydrate could be used in the study for orthopoxvirus-induced diseases.
  • HY-170799
    HNC-1664
    		Inhibitor
    HNC-1664 is the orally active inhibitor for RNA-dependent RNA polymerase (RdRP). HNC-1664 exhibits broad-spectrum antiviral activity against coronavirus (SARS-CoV-2 wildtype and its mutants XBB.1.18, HK.3.1, BF.7.14, BA.1HCoV-229E, HCoV-OC43) and arenavirus. HNC-1664 exhibits anti-infectious activity in SARS-CoV-2 Delta infected mouse models.
  • HY-P990810
    Anti-LCMV Nucleoprotein Antibody (VL-4)
    		Inhibitor
    Anti-LCMV Nucleoprotein Antibody (VL-4) is rat-derived IgG2a κ type antibody inhibitor, targeting to LCMV nucleoprotein. Anti-LCMV Nucleoprotein Antibody (VL-4) reacts with lymphocytic choriomeningitis virus (LCMV) nucleoprotein. Anti-LCMV Nucleoprotein Antibody (VL-4) stain LCMV-infected cell internally with no surface staining. Anti-LCMV Nucleoprotein Antibody (VL-4) can be used for the detections of immunofluorescence and flow cytometry in LCMV infection.
  • HY-P0323
    GP(33-41)
    		Inhibitor
    GP(33-41), a 9-aa-long peptide, is the optimal sequence of the GP1 epitope of lymphocytic choriomeningitis virus, and can upregulate H-2Db molecules at the RMA-S (Db Kb) cell surface with a SC50 of 344 nM.